Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues by Skalicky, Susanna et al.
 
 
 University of Groningen
Combining laser microdissection and microRNA expression profiling to unmask microRNA
signatures in complex tissues






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Skalicky, S., Zwiers, P. J., Kuiper, T., Schraml, E., Hackl, M., & Molema, G. (2019). Combining laser
microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues.
Biotechniques, 67(6), 276-285. https://doi.org/10.2144/btn-2019-0032
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
www.BioTechniques.com276 No. 6 | Vol. 67 | © 2019 Matthias Hackl
Reports
ABSTRACT
Neglecting tissue heterogeneity during the analysis 
of microRNA (miRNA) levels results in average 
signals from an unknown mixture of different cell 
types that are difficult to interpret. Here we demon-
strate the technical requirements needed to obtain 
high-quality, quantitative miRNA expression infor-
mation from tumor tissue compartments obtained by 
laser microdissection (LMD). Furthermore, we show 
the significance of disentangling tumor tissue hetero-
geneity by applying the newly developed protocols 
for combining LMD of tumor tissue compartments 
with RT-qPCR analysis to reveal compartment-
specific miRNA expression signatures. An important 
advantage of this strategy is that the miRNA signature 
can be directly linked to histopathology. In summary, 
combining LMD and RT-qPCR is a powerful approach 
for spatial miRNA expression analysis in complex 
tissues, enabling discovery of disease mechanisms, 
biomarkers and drug candidates.
METHOD SUMMARY
Laser microdissection was used on snap-frozen 
and cryostat-cut human tumor tissues to isolate 
tumor cells, stromal cells and tumor microvascular 
compartments. Total RNA was extracted from these 
compartments and used for highly parallelized 
microRNA (miRNA) quantification in primer-coated 
384-well plates for high-throughput characterization 
of miRNA transcription. Compartment-specific 
miRNA signatures were thus revealed, which creates 
novel insights into the molecular status of different 
cell types that are located within the complex, heter-
ogenic tumor tissue.
Laser microdissection (LMD) was 
developed in 1996 at the National 
Cancer Institute [1]. It is an automated 
sample-preparation technique that 
enables isolation of specific cells 
from a mixed population under micro-
scopic visualization. This technique 
is characterized by the use of a laser 
coupled to an inverted light micro-
scope to selectively extract a defined 
cell population of interest from a 
heterogeneous mixture of cells in a 
typical tissue section [2]. LMD allows 
us to combine histopathological 
information obtained by a dedicated 
pathologist with unmasking the 
molecular signatures associated with 
the histopathological findings. There 
is no need to enzymatically disrupt 
the tissue to obtain single cells, which 
results in no disturbance in the 
biomolecule make-up or activation 
status of the cells under study [3].
microRNAs (miRNAs) are 
short, noncoding RNAs that act 
as important post-transcriptional 
regulators of gene expression, 
including many key regulatory 
proteins involved in cancer devel-
opment and progression. They can 
inhibit or enhance the expression 
of oncogenes or tumor suppressor 
genes, therefore profoundly affecting 
the biology of cancer [4]. The 
transcriptional regulation of miRNAs 
is mediated by RNA polymerase II 
promoters for intergenic miRNAs, 
or depends on the host gene in case 
of intronic miRNAs. Thus, miRNA 
transcription is a dynamic and tightly 
regulated process, and as a conse-
quence every tissue exhibits a highly 
specific miRNA pattern that distin-
guishes it from other tissue types [5]. 
These patterns are highly conserved 
across species [6], and eventually are 
the origin of distinct extracellular 
miRNA profiles in cell-free biofluids 
such as serum and plasma [7]. This 
knowledge generated in recent 
decades now provides the basis for 
using circulating miRNAs as specific 
biomarkers for diagnosis of organ 
injury due to drug toxicity [8], or for 
the application as tumor biomarkers 
for the identification of cancer tissue 
origins [9].
However, one of the challenges 
that need to be solved in order to 
make a rational choice for miRNAs 
as biomarker or drug targets is posed 
by exactly this intrinsic heteroge-
neity in miRNA expression between 
different cell types and intrinsic 
cellular complexity of an organ or 
tissue. Here, we describe a novel 
protocol that consists of the combi-
nation of LMD with a highly sensitive 
PCR-based quantification method for 
miRNAs. The protocol allows us to 
increase the resolution of assigning 
production of miRNAs to cell subsets 
within a complex tissue, including 
tumors, and to disentangle a complex 
profile of signals caused by hetero-
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Human Rights and Biomedicine). A 
dedicated pathologist histologically 
assessed hematoxylin-stained cryostat-cut 
tumor sections and judged them as PDAC 
and CRC, and assisted in annotating tumor 
cell and stromal areas for further processing 
and handling in the LMD procedure.
Laser microdissection
9 μm cryostat-cut tumor sections were 
used to laser microdissect tumor tissue 
(TT), stromal tissue (ST) and tumor 
endothelial cells (TECs). For this purpose, 
the cryosections were placed on polyeth-
ylene naphthalate (PEN) membrane slides 
(Carl Zeiss B.V., Breda, The Netherlands) 
and stained with hematoxylin to visualize 
tumor tissue histology. For visualization of 
TEC, cryosections were placed on 
PET-Frame Slides (Leica Microsystems, 
Wetzlar, Germany) and stained with FITC-
labeled Ulex Europaeus Agglutinin (UEA I, 
Brunschwig Chemie, Amsterdam, The 
Netherlands). Tissue regions of interest 
were selected using LMD6500 software 
v7.0, (Leica Microsystems) and total areas 
varying from 1 × 104 to 2 × 106 μm2 were 
microdissected using the LMD6500 system 
(Leica Microsystems). Laser microdis-
sected material was collected in a 0.5-μl 
adhesive cap (Carl Zeiss B.V.) and stored at 
-80°C until further processing.
Total RNA extraction
RNA extraction was performed using the 
miRNeasy Micro kit (Qiagen, Germany). Prior 
to extraction, 1 μl of a synthetic RNA mix 
(Qiagen, Germany) consisting of three 
different synthetic control RNAs (UniSp2, 
2 fmol/ml; UniSp4, 0.02 fmol/ml; UniSp5, 
0.0002 fmol/ml) was added to 700 μl QIAzol. 
For sample lysis, 350 μl QIAzol was added in 
two steps to the tissue and vortexed carefully 
for 20 s inbetween. Lysates were centrifuged 
at low speed and transferred to a 1.5-ml 
Eppendorf tube. The samples were homog-
enized by vortexing for 1 min and placed at 
room temperature (15–25°C) for 5 min. 140 μl 
chloroform was added followed by vigorous 
mixing and incubation at room temperature 
for 2–3 min. Samples were centrifuged for 
15 min at 12,000×g at 4°C. The upper aqueous 
phase was transferred to a new tube, precip-
itated and purified on a QIAcube liquid-
handling robot using the miRNeasy Micro kit 
(Qiagen, Hilden, Germany) according to the 
manufacturer instructions, with the following 
modification: glycogen (Ambion, TX, USA) 
was added to the aqueous phase to a final 
concentration of 50 μg/ml. RNA was eluted 
in a single round in 30-μl nuclease-free water 
and stored at 80°C. Total RNA yields from 
PDAC tumor compartments were assessed 
using the Agilent Bioanalyzer 2100 platform 
(Supplementary Figure S1) together with the 
RNA 6000 Pico kit (Agilent Technologies, CA, 
USA) and used for correlation against 
reference gene expression by Pearson corre-
lation.
miRNA RT-qPCR quantification
Equal volumes of total RNA extracts from 
every sample were used directly for reverse 
transcription into cDNA using the miRCURY 
LNA RT Kit (Qiagen, Hilden, Germany). 
Universal reverse transcription reactions 
for RT-qPCR screening were performed as 
either 10- or 45-μl reactions containing 4- 
or 18-μl total RNA input, respectively. A 
synthetic cDNA spike-in (cel-miR-39-3p, 
0.002 fmol/μl) was added to the RT mix to 
monitor variance in RT efficiency as well 
as to detect the presence of enzyme inhib-
itors. For qPCR analysis, cDNA samples 
were diluted 1:100. qPCR reactions were 
performed as 10-μl reactions in 96-well 
plates for analysis of individual miRNAs. 
For screening purposes, 384-well plates 
(Human Panel I V4, Exiqon, Denmark) were 
used, which contained 375 miRNA-specific 
primers, four spike-in primers (UniSp2, 
UniSp4, UniSp5 and cel-miR-39-3p), three 
distinct PCR control wells with precoated 
DNA templates and primers referred to as 
‘interplate-control 3’ (IPC3) and one 
negative control well. All primers were 
obtained from Qiagen and use locked 
nucleic acid (LNA) technology for optimi-
zation of hybridization efficiencies. For 
PCR the miRCURY LNA SYBR Green PCR 
mix was used (Qiagen, Hilden, Germany) 
and plates were prepared using an 
Eppendorf epMotion liquid-handling robot. 
PCR amplification was conducted in a 
Roche LC480 II instrument (Roche, 
Hildesheim, Germany) with the following 
settings: 95°C for 10 min, 45 cycles of 95°C 
for 10 s and 60°C for 60s, followed by 
melting curve analysis. Cq values were 
computed using the second derivative 
maximum method provided with the 
LC480 II software.
For targeted miRNA analysis, Cq values 
were normalized using the delta-Cq (dCq) 
method to the global mean of all RNA 
spike-in controls (UniSp2, UniSp4, UniSp5) 
to account for any technical variation intro-
duced during the analysis. Other small 
noncoding RNAs, specifically 5S rRNA, U6 
snRNA and U48 snRNA, were assessed 
to account for differences in total RNA 
content/cell number between the tissue 
compartments. In order to account for 
differences in total RNA content in LMD 
samples due to differences in cell numbers 
or compartment sizes (especially relevant 
for whole tumor), global mean normalization 
was performed [10].
mRNA RT-qPCR quantification
For mRNA quantification the TATAA SYBR 
Grandmaster mix kit (TATAA Biocenter, 
Sweden) was used. 8 μl of total RNA extracts 
were used for reverse transcription and all 
steps were carried out according to recom-
mendations by the manufacturer. PCR ampli-
fication was performed in a 96-well format 
in a Roche LC480 II instrument (Roche, 
Germany) with the following settings: 95°C 
for 30 s followed by 45 cycles of 95°C for 5 s, 
63°C for 15 s and 72°C for 10 s, and subse-
quent melting curve analysis (data not 
shown). To calculate the cycle of quantifi-
cation values (Cq-values), the second deriv-
ative method was used. Primer sequences 
used for GAPDH and ACTB are listed in 
Table 1.
Table 1. Primer sequences used for mRNA qRT-PCR analysis.
Gene Forward primer Reverse primer
GAPDH TACACTGAGGACCAGGTTGTG TTGACGAAGTGGTCGTTGAG
ACTB  CACGCCATCCTGCGTCTGGA AGCACCGTGTTGGCGTAGAG
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Figure 1. Linearity between laser microdissected tissue compartment area and miRNA quantification enables downscaling of sample input obtained 
by laser microdissection to areas of 10,000 μm2. 9 μm cryostat-cut colorectal carcinoma tumor tissue sections were subjected to laser microdis-
section to yield TT, ST and TEC at different surface areas (see also ‘Materials & methods’ section for information). Targeted RT-qPCR was used for 
quantification of two spike-in controls, which were either added prior to RNA extraction (RNA spike-in UniSp4) or during cDNA synthesis (cDNA 
spike-in [cel-miR-39]), three miRNAs (miR-21-5p, miR-126-3p and miR-34a-5p), as well as one reference noncoding RNA (U6 snRNA) in total 
RNA extracts derived from tissue compartments of varying size (1 × 104–2 × 106 μm2). (A) Spike-in controls show that RNA isolation and reverse 
transcription efficiency are independent of the compartment area size. (B–D) A strictly linear relation between laser microdissection area and qPCR 
signal was found in all tumor compartments. (E) miR-126-3p expression normalized to laser microdissected μm2 input in the RT-qPCR analysis. 
Each dot represents a compartment area between 1 × 104 and 2 × 106 μm2. Differences in miR-126-3p levels between compartments can be detected 
irrespective the compartments. 
ST: Stromal tissue; TEC: Tumor microvasculature; TT: Tumor tissue. 
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Statistical analysis
Principal component analysis (PCA) was 
performed using Clustvis [11] to perform 
unsupervised clustering. Medcalc was 
used for Pearson correlation analysis 
between total RNA concentration and 
reference gene levels.
RESULTS & DISCUSSION
RT-qPCR can be applied for miRNA 
quantification in LMD tumor tissue 
compartments
One of the main challenges associated with 
RNA quantification in LMD tissue compart-
ments that measure as low as 10,000 μm2 
surface with 9–10-μm thickness is the low 
total RNA yield, which generally ranges 
between 10 and 500 pg/μl. This is well below 
the limit of detection for photometric quanti-
fication methods such as Nanodrop, and 
potentially challenging to quantify using 
fluorescence-based methods. Therefore, we 
initially investigated the feasibility of miRNA 
quantification using an RT-qPCR platform 
on the basis of samples from human CRC 
tissue. This tissue was compartmentalized 
by LMD into TT, ST and tumor microvascu-
lature (mainly consisting of tumor endothelial 
cells [TECs]). For every compartment LMD 
replicates with areas varying between 
104 μm2 and 2 × 106 μm2 were generated at 
Vivomicx. miRNA quantification was 
performed at TAmiRNA: one synthetic 
spike-in control (RNA spike-In UniSp4) was 
added prior to RNA extraction, and one 
spike-in (cDNA spike-in cel-miR-39) was 
added to the total RNA in order to monitor 
the efficiencies of RNA extraction and 
reverse transcription, respectively. Both 
spike-ins, three endogenous miRNAs 
(miR-126-3p, miR-21-5p, miR-34a-5p) as well 
as one reference RNA (U6 snRNA) were 
analyzed by RT-qPCR.
The results obtained for RNA and 
cDNA spike-in controls showed that RNA 
extraction and RT efficiencies were compa-
rable across all samples and independent of 
the tissue/RNA input amounts (Figure 1A). 
In all three compartments a strict linearity 
between tissue input and RT-qPCR signals 
was observed for endogenous miRNAs and 
U6 snRNA (Figure 1B–D). When focusing 
on miR-126-3p expression, a miRNA previ-
ously shown to be enriched in endothelial 
cells [12,13], this linearity between input of 
material in μm2 and signal in the RT-qPCR 
analysis was confirmed. The observed 
difference in miR-126-3p expression 
between tumor cells, stromal cells and tumor 
microvasculature was not dependent on the 
input but on the compartment under inves-
tigation (Figure 1E).
From this we concluded that differ-
ences in miRNA expression between the 
compartments can be reliably detected 
independent of the compartment size. This 
is an important conclusion, because the 
smaller the laser-microdissected compart-
ments, the lower the risk of cross-contami-
nation with other cell types, and the shorter 
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Figure 2. miRNA screening and clustering in tissue compartments. (A) Total RNA extracted from 
two colorectal carcinoma samples (whole tumor) as well as the respective tumor cell, tumor stromal 
cell and TEC compartments was used for screening of 384 distinct miRNA species. On average, 
more than 250 miRNAs were detected in tissue compartments above the limit of detection. (B) The 
principal component analysis conducted on the basis of 255 miRNAs that were detected across all 
compartments as well as whole tumor. PC1 explains 57.2% of the overall variance in miRNA levels, 
while PC2 explains 20.3%. The relative positioning of samples in the plot provides information 
about their similarity in terms of microRNA expression. 
PC1: Principal component 1; PC2: Principal component 2; TEC: Tumor endothelial cell.
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Normalization strategies for spatial 
miRNA profiling within or across tumor 
tissue compartments
In the next step, we aimed to address the 
issue of normalization to enable comparison 
of miRNA expression levels within one 
tissue compartment (e.g., tumor cells) 
between different tumor specimens. 
Normalization can be achieved by keeping 
the compartment areas constant across all 
samples. By monitoring RNA extraction 
efficiency using spike-in controls (Figure 1), 
the technical variability and quality of RNA 
isolation, reverse transcription and PCR 
amplification can be assessed. However, 
especially when comparing miRNA 
expression between different tissue 
compartments that are composed of 
different cell types, normalization to the 
size of the laser-microdissected 
compartment will bias the results because 
the number of cells contained in a defined 
compartment area will be different 
depending on the type of cells. Conse-
quently, normalization needs to be 
performed at either the total RNA level by 
using highly sensitive quantification 
methods capable of detecting picogram 
amounts of RNA, or by using reference 
RNAs. The latter are presumably transcribed 
at constant levels across various cell types 
and are therefore correlated to the amount 
of total RNA/number of cells in a specific 
tissue compartment.
We addressed this issue by compart-
mentalizing a PDAC sample into TT, ST and 
TEC (270,000 μm2 per compartment), and 
analyzing the levels of three non-coding 
RNA references (U6 snRNA, U48 snRNA and 
5S rRNA) and two coding RNA references 
(GAPDH, ACTB), respectively. Cq-values 
obtained for five reference gene candidates 
across three tumor compartments (tumor, 
stroma and vasculature) were correlated 
to the log2-transformed total RNA concen-
tration in each compartment, which was 
determined using the Agilent RNA 6000 
Pico kit. We observed the highest corre-
lation between U6 snRNA levels and total 
RNA (Pearson correlation coefficient [PCC] 
0.98), but the other four reference RNAs 
also exhibited good correlation to total 
RNA (ACTB: 0.81; GAPDH: 0.80; U48: 0.86; 5S 
rRNA: 0.74). From these data, we concluded 
that the tested panel of reference RNAs 
and their respective geometric means are 
suitable for normalization of sample input 
variability introduced by differences in cell 
numbers in the laser-microdissected tissue 
compartments (TT, ST and TEC).
Table 2. Top 20 tumor compartment-enriched microRNAs.
Tumor-enriched
microRNAs
Global mean normalized level (dCq) Enrichment factor (2ddCq)
Whole 









1 hsa-miR-182-5p 1.67 2.46 -3.62 -1.11 28.26 0.05 0.69
2 hsa-miR-183-5p 0.63 1.26 -4.53 -1.80 21.46 0.05 0.89
3 hsa-miR-375 2.45 3.41 -0.90 -0.82 19.34 0.22 0.24
4 hsa-miR-200b-3p 6.89 7.51 1.72 4.76 19.24 0.05 1.10
5 hsa-miR-96-5p 0.82 2.66 -1.94 -0.53 14.81 0.12 0.54
6 hsa-miR-200a-3p 4.45 6.20 0.95 3.70 14.63 0.06 1.09
7 hsa-miR-135b-5p 3.54 4.40 -0.66 1.73 14.60 0.08 0.91
8 hsa-miR-194-5p 6.64 7.49 2.54 4.93 13.48 0.08 0.94
9 hsa-miR-196a-5p 1.35 2.31 -2.57 -0.30 13.41 0.08 0.89
10 hsa-miR-301b -4.09 -0.76 -5.16 -3.72 12.82 0.13 0.59
11 hsa-miR-147b -5.65 -3.24 -7.57 -6.20 12.52 0.14 0.58
12 hsa-miR-17-5p 0.64 2.79 -2.18 0.49 12.37 0.07 1.14
13 hsa-miR-429 3.35 4.74 -0.08 2.35 12.15 0.08 1.01
14 hsa-miR-215 5.91 6.59 1.73 4.30 11.90 0.08 1.10
15 hsa-miR-584-5p -3.69 -1.68 -6.18 -4.20 11.40 0.11 0.83
16 hsa-miR-135a-5p -0.22 0.64 -4.04 -1.71 11.38 0.09 0.99
17 hsa-miR-192-5p 6.79 7.82 3.14 5.65 10.75 0.08 1.12
18 hsa-miR-141-3p 7.11 8.21 3.82 5.92 10.15 0.11 0.93
19 hsa-miR-200c-3p 7.88 8.46 3.98 6.31 9.92 0.09 1.06
20 hsa-miR-20a-5p 6.60 8.59 4.60 6.14 9.31 0.15 0.73
dCq values reflect the log2-transformed expression level. Positive values mean levels higher than the global mean (high abundant), while negative 
values mean levels below the global mean, that is, low abundance.
dCq: Delta-Cq; ST: Stromal tissue; TEC: Tumor endothelial cell; TT: Tumor tissue.
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Large-scale profiling of miRNA levels 
in human colorectal carcinoma tissue 
compartments identifies signatures 
of tumor, stroma & microvasculature-
enriched miRNAs
Next, we investigated whether the total RNA 
yield from tumor compartments was suffi-
cient to conduct large-scale miRNA 
screening by RT-qPCR to enable unbiased 
discovery of miRNA signatures specific for 
tumor, stroma and microvasculature. LMD 
was performed on two CRC specimens from 
two different patients to obtain total RNA 
from the three compartments (2.7 × 105 μm2), 
as well as a whole-tumor sections (9 μm). In 
each sample the levels of 372 distinct miRNA 
species as well as 12 endogenous or 
synthetic control RNAs were analyzed using 
RT-qPCR in 384-well plates (see Supple-
mentary File 1 for complete information on 
Cq-values in all samples). Figure 2A depicts 
the number of miRNAs that were above the 
limit of quantification (Cq <40, green), at the 
limit of detection (Cq = 40, yellow), as well 
as the number of miRNAs that were below 
the limit of detection (Cq >40). We observed 
the highest detection rates in whole-tumor 
specimens, 359 and 347 miRNAs above the 
LoQ, respectively, which is likely due to the 
higher RNA yield from whole-tumor sections 
compared with those from the laser-micro-
dissected compartments (Figure 2A). Fewer 
miRNAs were detected in tumor compart-
ments; however, 255 miRNAs were detected 
across all eight specimens. Unsupervised 
clustering analysis of whole tumor and 
tumor compartments was performed on the 
basis of this common set of 255 miRNAs 
using principal component analysis (PCA), 










































































































































































































































































Figure 3. Identification of compartment 
specific miRNA profiles. miRNA profiles were 
assessed in laser-microdissected colorectal 
carcinoma tissue compartments using 384-well 
microRNA array platform technology. Fold 
changes in miRNA expression levels between 
compartments were calculated and plotted to 
highlight miRNAs with strong enrichment in the 
respective compartments. (A) Tumor-enriched 
miRNAs, (B) stroma-enriched miRNAs and (C) 
tumor  microvasculature-enriched miRNAs.
ST: Stromal tissue; TEC: Tumor microvascu-
lature; TT: Tumor tissue.
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that in one particular compartment 
expression of some miRNAs may be 
completely lacking. PC1 and PC2 were found 
to explain 77.5% of the overall variance in 
miRNA levels (Figure 2B). Clustering of 
samples in the PCA plot showed high 
similarity (short distance) between the two 
biological replicates of tumor compart-
ments, while large differences (large 
distances) were observed between the 
compartments as well as whole tumor. This 
suggests the existence of compartment-
specific miRNA signatures.
In order to identify tumor, stroma and 
tumor microvascular signatures, pair-wise 
comparison of normalized miRNA levels 
between compartments was performed 
(Figure 3A–C). Figure 3A exemplifies several 
tumor-enriched miRNAs such as miR-17-5p, 
miR-182-5p and miR-200b-3p, which have 
all been previously shown to be drivers 
of oncogenic phenotypes [14–16]. On the 
other hand, miR126-3p, which is known to 
be more highly expressed by endothelial 
cells [17–19], was found to be most abundant 
in the tumor microvasculature compartment 
alongside miR-133b. The latter is known to 
be enriched in muscle tissue, including 
vascular smooth muscle cells (VSMCs) [20], 
and may possibly be upregulated by either 
pericytes or endothelial cells that make up 
the tumor microvasculature by conditions 
that prevail in the tumor microenvironment. 
miRNAs that were found most enriched in 
stroma were miR-99a-3p and miR-154-5p, 
which are both known to be promoters 
of epithelial-to-mesenchymal transition 
and highly abundant in fibroblasts [21,22]. 
Interestingly, miR-21-5p, which has been 
acknowledged several times as a miRNA 
eliciting oncogenic effects, as well as 
being associated with poor survival of CRC 
patients, was found to be expressed highest 
in the stroma compartment, followed by 
vasculature and tumor (Figure 3A–C).
Extended lists of top 20 compartment-
enriched miRNAs were generated based on 
fold enrichment in the target compartment 
compared with the average of the remaining 
compartments (Tables 2–4). Besides 
consisting of miRNAs previously reported 
by others to be associated with tumor 
cells, the stromal compartment and tumor 
microvasculature, as discussed above, the 
table also provides a glance at miRNAs 
that have not yet been identified in specific 
com partments.
Table 3. Top 20 stroma compartment-enriched microRNAs.
Stroma- enriched
microRNAs
Global mean normalized level (dCq) Enrichment factor (2ddCq)





hsa-miR-99a-3p -3.67 -7.48 -1.00 -6.20 0.07 57.26 0.26
hsa-miR-154-5p -1.07 -5.68 0.54 -3.48 0.05 34.82 0.53
hsa-miR-299-5p -3.42 -7.05 -1.27 -5.32 0.07 30.31 0.45
hsa-miR-337-3p -2.96 -7.48 -1.58 -4.65 0.05 22.50 0.92
hsa-miR-379-5p -1.74 -7.48 -0.46 -1.82 0.01 18.34 4.43
hsa-miR-708-5p 1.43 -3.25 2.68 0.43 0.04 17.11 1.64
hsa-miR-100-5p 3.89 -0.55 5.28 2.96 0.04 16.85 1.51
hsa-miR-125b-5p 6.22 2.16 7.70 5.71 0.04 13.59 1.71
hsa-miR-199b-5p 2.14 -0.42 4.48 2.09 0.08 12.53 1.04
hsa-miR-99a-5p 2.68 -0.90 3.83 1.34 0.09 12.20 0.92
hsa-miR-376a-3p -2.42 -6.19 -1.05 -2.99 0.06 11.65 1.55
hsa-miR-199a-3p 4.52 0.01 5.51 4.02 0.04 11.33 2.39
hsa-miR-199a-5p 2.58 -0.66 4.69 3.04 0.04 11.33 2.03
hsa-miR-411-5p -1.97 -4.59 -0.71 -3.68 0.19 10.77 0.49
hsa-miR-214-3p 1.75 -1.41 3.64 1.94 0.05 10.39 1.77
hsa-miR-145-5p 6.24 2.91 8.09 7.03 0.04 8.74 2.88
hsa-miR-377-3p -5.75 -7.48 -3.55 -5.79 0.14 8.51 0.83
hsa-miR-342-3p 3.05 0.05 4.32 2.48 0.10 8.31 1.22
hsa-miR-370 -4.16 -7.48 -2.73 -4.05 0.06 8.19 2.08
hsa-miR-138-5p -4.49 -7.48 -3.43 -5.32 0.12 7.85 1.10
dCq values reflect the log2-transformed expression level. Positive values mean levels higher than the global mean (high abundant), while negative 
values mean levels below the global mean, that is, low abundance.
dCq: Delta-Cq; ST: Stromal tissue; TEC: Tumor endothelial cell; TT: Tumor tissue.
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FUTURE PERSPECTIVE
The current study was initiated to investigate 
the possibilities and limitations of combining 
compartmentalization of complex tissues 
by LMD with miRNA profiling. Such a strategy 
would allow us to deconstruct the molecular 
complexity of tissues, including tumor 
tissues and organ tissues, for application in 
drug development and biomarker discovery.
The ability to focus miRNA analysis on 
specific cellular compartments within a 
heterogeneous, complex tissue made up 
of several cell types is essential to improve 
our understanding of the biological role(s) 
that miRNAs play during various stages of 
onset and progression of disease [23]. For 
example, Hu et al. have shown that colon 
cancer tissue levels of miR-196 are infor-
mative of chemoresistance of this type of 
cancer [24]. Compartment-specific miRNA 
expression profiles generated in this study 
show that miR-196a-5p is highly enriched 
in tumor cells compared with stroma and 
vasculature (Table 2). Tumor angiogenesis 
is essential for tumor growth and metastasis. 
Wang et al. have reviewed the importance 
of miRNA regulation in tumor angiogenesis, 
highlighting for example the relevance of 
miR-126, miR-503, miR-497, miR-218 and 
miR-195 for the regulation of VEGF, VEGF 
inducers and VEGF independent factors [25]. 
Our data confirm that all of these miRNAs 
are highly expressed in the microvascular 
compartment compared to stroma and 
tumor, since all miRNAs rank within the top 
20 TEC-enriched miRNAs (Table 4). Thus, 
the combination of techniques allowing 
physical separation of such tissues into more 
homogeneous compartments with sensitive 
analytical methods is essential to obtain inter-
pretable results from tissue analysis. Using 
this approach, we were able to demonstrate 
profound differences in miRNA expression 
signatures between whole tumor tissue and 
subsets of cell types in different compart-
ments within the tumor (Figure 4A). The 
approach presented here is crucial for the 
discovery of molecular differences between 
‘healthy and diseased’ tissues, as it does not 
change the status of the cells as is seen with, 
for example, trypsin treatment, to release 
them for subsequent molecular analyses. 
In addition, information about the original 
location of the cells that we have molecularly 
mapped is retained, enabling combining of 
the molecular map with histopathological 
information. It thus provides an important 















1 hsa-miR-126-3p 4.98 1.61 5.86 7.45 0.03 2.53 13.11
2 hsa-miR-126-5p 2.87 -0.94 3.26 4.57 0.03 2.74 10.61
3 hsa-miR-383 -12.50 -7.48 -7.57 -4.33 0.35 0.32 9.19
4 hsa-miR-451a 2.86 -0.74 0.78 3.21 0.15 0.73 9.14
5 hsa-miR-187-3p -7.59 -7.48 -6.98 -4.15 0.26 0.45 8.47
6 hsa-miR-34c-3p -4.59 -4.39 -7.57 -2.98 1.85 0.07 7.99
7 hsa-miR-133b -3.18 -5.45 -2.16 -0.84 0.06 1.99 7.78
8 hsa-miR-503-5p -5.11 -5.38 -5.67 -2.74 0.44 0.33 6.88
9 hsa-miR-486-5p -2.73 -5.25 -4.29 -2.06 0.24 0.64 6.55
10 hsa-miR-373-3p -12.41 -6.23 -7.57 -4.25 0.80 0.20 6.30
11 hsa-miR-144-3p -4.73 -5.21 -5.33 -2.62 0.43 0.38 6.25
12 hsa-miR-133a -2.87 -5.15 -0.58 -0.72 0.04 5.11 4.44
13 hsa-miR-379-5p -1.74 -7.48 -0.46 -1.82 0.01 18.34 4.43
14 hsa-miR-30a-5p -0.19 -3.28 0.92 0.94 0.05 4.26 4.35
15 hsa-miR-124-3p -7.00 -5.56 -4.97 -3.28 0.37 0.68 3.96
16 hsa-miR-218-5p -1.51 -5.54 -0.73 -1.18 0.04 6.18 3.88
17 hsa-miR-143-3p 5.17 1.57 6.07 5.72 0.05 5.37 3.74
18 hsa-miR-497-5p 0.10 -2.63 1.58 1.19 0.06 4.94 3.27
19 hsa-miR-382-5p -2.03 -5.97 -1.57 -2.19 0.06 5.71 2.99
20 hsa-miR-195-5p 2.83 -0.01 4.28 3.71 0.06 5.39 2.97
dCq values reflect the log2-transformed expression level. Positive values mean levels higher than the global mean (high abundant), while negative 
values mean levels below the global mean, that is, low abundance.
dCq: Delta-Cq; ST: Stromal tissue; TEC: Tumor endothelial cell; TT: Tumor tissue.
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new combination of technologies to inves-
tigate mechanisms of disease, discovery of 
novel biomarkers and targets for therapeutic 
intervention, and monitor the effects of drug 
candidates on specific cell types within the 
target tissue [26,27] (Figure 4B).
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Figure 4. Summary. (A) Malignant (as well as healthy) tissues are mixtures of multiple cell types: tumor cells, stromal cells, microvasculature – mainly 
endothelial cells – and often other specialized cell types (e.g., tumor-infiltrating lymphocytes). The molecular analysis of whole-tumor tissue samples 
results in a mixture of signals with unclear origin. Combining LMD to obtain pre-selected cell types with highly sensitive RNA expression analysis is 
a crucial step toward obtaining interpretable results from complex tissue analysis. (B) This above-depicted strategy enables improvement of identifi-
cation of molecular signatures that underlie disease processes and responses of multiple cell types to treatment, and as such represents an important 
novel fundament for drug discovery and drug development.
CRC: Colorectal cancer; LMD: Laser microdissection; NA: Not assessed; ST: Stromal tissue; TEC: Tumor endothelial cell; TT: Tumor tissue.
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